Related Experiment Video
Updated: Oct 25, 2025

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
Published on: October 7, 2017
Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
Shintaro Sakai1,2, Yoshiro Morimoto1,2, Yusuke Matsuzaka1,2
1Department of Neuropsychiatry, Unit of Translation Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Abstract:
Tardive dyskinesia (TD) is a common side effect of antipsychotics, and it remains a persistent and challenging problem. The blonanserin transdermal patch, developed in Japan and launched in September 2019, is the first antipsychotic transdermal treatment. Here, we describe a patient with schizophrenia who exhibited markedly improved orofacial dyskinesia after switching from blonanserin tablets to blonanserin transdermal patches. We speculate that the patch formulation might have led to more stable plasma blonanserin levels, thus reducing the side effects. Specifically, the patch formulation might have contributed to stable plasma levels via the continuous and direct absorption of blonanserin through the skin.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Antidepressant Drugs: MAOIs and Other Agents
Cholinergic Antagonists: Pharmacokinetics
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Psychosis: Goals of Pharmacotherapy

